Harvest One Cannabis Inc. (
TSX: V.HVST,
HRVOF,
Forum), on Wednesday released an update on its Satipharm AG unit.
Based in Cham, Switzerland, Satipharm AG is the pharmaceutical division of Harvest One and is a pioneer in the development and distribution of medical cannabis based pharmaceutical and nutraceutical products.
Harvest One said Satipharm recently received a “Free Sale Certificate” by German authorities, which reduces constraints for international exports and removes final regulatory trading impediments with other EU jurisdictions.
More information can be found
here.
Harvest One was in the news recently when
the company announced through its United Greeneries (UG) subsidiary, that it has closed an arm’s length acquisition of its current production facility in Duncan, B.C., for a cash purchase price of $2.8 million.
FULL DISCLOSURE: Harvest One Cannabis Inc. is a paid client of Stockhouse Publishing.